References
Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E (2009) RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 18:1085–1102
Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Rev Anticancer Ther 9:1125–1134
Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721–729
Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172
Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736–1740
Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg Oct 15. doi:10.1016/j.bjoms.2009.08.030
Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Proffered Paper sessions 7(3):12
Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Presidential session II 7(3):2–3
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C, Boukovinas I, Koloutsos G, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362
Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475–483):e473
Kyrgidis A, Vahtsevanos K (2009) Osteonecrosis of the jaw in patients receiving oral bisphosphonates. Osteoporos Int. doi:10.1007/s00198-009-01089-5
Kyrgidis A, Vahtsevanos K (2009) "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Investig 13:479–480
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kyrgidis, A., Toulis, K.A. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 22, 369–370 (2011). https://doi.org/10.1007/s00198-010-1177-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-010-1177-6